Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
FSD PHARMA INC-CLASS B (HUGE) Stock Price & Overview
NASDAQ:HUGE • CA35954B4047
Current stock price
0.0899 USD
-0.01 (-10.1%)
At close:
0.0916 USD
+0 (+1.89%)
After Hours:
The current stock price of HUGE is 0.0899 USD. Today HUGE is down by -10.1%. In the past month the price decreased by -40.82%. In the past year, price decreased by -93.22%.
HUGE Key Statistics
52-Week Range0.072 - 1.6799
Current HUGE stock price positioned within its 52-week range.
1-Month Range0.072 - 0.3663
Current HUGE stock price positioned within its 1-month range.
- Market Cap
- 3.635M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
HUGE Stock Performance
Today
-10.1%
1 Week
+15.11%
1 Month
-40.82%
3 Months
-71.82%
Longer-term
6 Months -89.23%
1 Year -93.22%
2 Years -90.11%
3 Years -95.09%
5 Years N/A
10 Years N/A
HUGE Stock Chart
HUGE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HUGE. When comparing the yearly performance of all stocks, HUGE is a bad performer in the overall market: 99.39% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
HUGE Earnings
Next Earnings DateNov 12, 2024
Last Earnings DateAug 9, 2024
PeriodQ1 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
HUGE Forecast & Estimates
7 analysts have analysed HUGE and the average price target is 7.83 USD. This implies a price increase of 8606.04% is expected in the next year compared to the current price of 0.0899.
Analysts
Analysts82.86
Price Target7.83 (8609.68%)
EPS Next YN/A
Revenue Next YearN/A
HUGE Financial Highlights
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-28.73M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
HUGE Ownership
Ownership
Inst Owners0.07%
Shares40.44M
Float34.63M
Ins Owners3.8%
Short Float %N/A
Short RatioN/A
HUGE Industry Overview
HUGE operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 29 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
48/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
32%
Outperformed 32% of sub-industries
3 Month Rank
63%
Outperformed 63% of sub-industries
6 Month Rank
26%
Outperformed 26% of sub-industries
Industry Fundamentals & Breadth
- Members
- 29
- New Highs
- 3.5%
- New Lows
- 10.3%
- Average ROE
- 17.5%
- Average Profit Margin
- 9.9%
- Average Operating Margin
- 19%
- Average P/E
- 5.2
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 0.5
HUGE Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HUGE
Company Profile
FSD Pharma, Inc. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
Company Info
IPO: 2018-05-29
FSD PHARMA INC-CLASS B
55 University Ave. , Suite 1003
TORONTO ONTARIO M5X 1A4 CA
CEO: Raza Bokhari
Employees: 10
Phone: 14168548884
FSD PHARMA INC-CLASS B / HUGE FAQ
Can you describe the business of FSD PHARMA INC-CLASS B?
FSD Pharma, Inc. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
What is the current price of HUGE stock?
The current stock price of HUGE is 0.0899 USD. The price decreased by -10.1% in the last trading session.
Does HUGE stock pay dividends?
HUGE does not pay a dividend.
How is the ChartMill rating for FSD PHARMA INC-CLASS B?
HUGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for FSD PHARMA INC-CLASS B?
FSD PHARMA INC-CLASS B (HUGE) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for FSD PHARMA INC-CLASS B?
FSD PHARMA INC-CLASS B (HUGE) will report earnings on 2024-11-12, before the market open.